Therapeutic Strategies against Leishmania and Trypanosoma
Pathogens, 2023 Human African trypanosomiasis (also known as sleeping sickness, with Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense as etiological agents), American trypanosomiasis (also known as Chagas disease, with Trypanosoma cruzi as the etiological
André L. S. Santos +5 more
doaj +1 more source
Spatially and genetically distinct African trypanosome virulence variants defined by host interferon-g response [PDF]
, 2007 We describe 2 spatially distinct foci of human African trypansomiasis in eastern Uganda. The Tororo and Soroti foci of <i>Trypanosoma brucei rhodesiense</i> infection were genetically distinct as characterized by 6 microsatellite and 1 ...
Anneli Cooper +19 more
core +1 more source
Delineating neuroinflammation, parasite CNS invasion, and blood-brain barrier dysfunction in an experimental murine model of human African trypanosomiasis [PDF]
, 2017 Although Trypanosoma brucei spp. was first detected by Aldo Castellani in CSF samples taken from sleeping sickness patients over a century ago there is still a great deal of debate surrounding the timing, route and effects of transmigration of the ...
Bradley, Barbara +2 more
core +1 more source
Nanobodies as tools to understand, diagnose, and treat African trypanosomiasis [PDF]
, 2017 African trypanosomes are strictly extracellular protozoan parasites that cause diseases in humans and livestock and significantly affect the economic development of sub-Saharan Africa.
Caljon, Guy +5 more
core +1 more source
Chemotherapy of Human African Trypanosomiasis
Interdisciplinary Perspectives on Infectious Diseases, 2009 Human Africa trypanosomiasis is a centuries-old disease which has disrupted sub-Saharan Africa in both physical suffering and economic loss. This article presents an update of classic chemotherapeutic agents, in use for >50 years and the recent ...
Cyrus J. Bacchi
doaj +1 more source
Updated estimate of the duration of the meningo-encephalitic stage in gambiense human African trypanosomiasis [PDF]
, 2015 Background: The duration of the stages of HAT is an important factor in epidemiological studies and intervention planning. Previously, we published estimates of the duration of the haemo-lymphatic stage 1 and meningo-encephalitic stage 2 of the ...
Chandramohan, Daniel +4 more
core +2 more sources
International Journal of Infectious DiseasesIntroduction: The development of neurological disorders following trypanosome brain infection has been recognised for over a century. However, an ongoing endeavour persists to comprehensively understand the neurocognitive and neuropathological changes ...
Dr Oluwashola Olaolu +7 more
doaj +1 more source
Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola. [PDF]
, 2008 OBJECTIVE: To compare the cost-effectiveness of eflornithine and melarsoprol in the treatment of human African trypanosomiasis. METHOD: We used data from a Médecins Sans Frontières treatment project in Caxito, Angola to do a formal cost-effectiveness ...
Adam +23 more
core +2 more sources
Integrated cost-benefit analysis of tsetse control and herd productivity to inform control programs for animal African trypanosomiasis [PDF]
, 2018 Animal African trypanosomiasis (AAT) and its tsetse vector are responsible for annual losses estimated in billions of US dollars ($). Recent years have seen the implementation of a series of multinational interventions.
Chilongo, K +7 more
core +1 more source
Immunophenotypic lymphocyte profiles in human african trypanosomiasis. [PDF]
PLoS ONE, 2009 Human African trypanosomiasis (HAT) is a deadly vector-born disease caused by an extracellular parasite, the trypanosome. Little is known about the cellular immune responses elicited by this parasite in humans.
Caroline Boda +9 more
doaj +1 more source